By Doug Macron

As the RNAi therapeutics field deals with the growing scrutiny of would-be investors and pharmaceutical industry partners, the wave of management shake-ups that swept the industry over the past few years (GSN 7/15/2010) continues, with key executives from at least four firms working on the technology having stepped down over the past 12 months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.